Wedbush Initiates Odyssey Therapeutics at Outperform With $30 Price Target

Canaccord Genuity Upgrades Allied Gold Corporation to Buy From Hold, Price Target is CA$44

Piper Sandler Downgrades Fulcrum Therapeutics to Underweight From Overweight, Adjusts PT to $3 From $23

Fulcrum Therapeutics (FULC) has an average rating of Hold and mean price target of $9.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts PT to $3 From $25

Fulcrum Therapeutics (FULC) has an average rating of Hold and mean price target of $9.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)